Pentasodium triphosphate

About

What it is and where it shows up.

Pentasodium triphosphate (STPP) is the sodium salt of triphosphoric acid produced commercially by neutralising phosphoric acid with sodium hydroxide and drying at high temperature. It is widely used in processed meats, seafood, dairy products, and bakery items as a sequestrant, texturizer, moisture-retention agent, and thickener.

Safety summary

The regulatory and scientific consensus.

JECFA has established a group Maximum Tolerable Daily Intake (MTDI) of 70 mg/kg body weight per day for phosphorus (as P) from all food-additive phosphate sources combined. Dietary intake of phosphate from food additives has more than doubled since the 1990s, raising concerns for cardiovascular and renal health. Individuals with chronic kidney disease are especially vulnerable, as impaired phosphate excretion can cause hyperphosphatemia, vascular calcification, and bone disease.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	JECFA group MTDI of 70 mg/kg bw (as P) covers pentasodium triphosphate and all food-additive phosphates. First established JECFA 26 (1982); reaffirmed JECFA 96. Expressed as elemental phosphorus from all additive sources combined.source
FSSAI (Food Safety and Standards Authority of India) (India)	Approved	Permitted food additive (INS 451i) under the Food Safety and Standards (Food Products Standards and Food Additives) Regulations, 2011, Appendix A. India's permitted list broadly harmonises with Codex Alimentarius.source
FDA (Food and Drug Administration) (United States)	Approved	Listed as Generally Recognized as Safe (GRAS) under 21 CFR 182.1810 for use as a general-purpose food additive. No specific numerical ADI has been set by FDA.source

Who should approach with care

Whose guidance would steer them away.

Kidney Disease — Inorganic phosphate additives are highly bioavailable; impaired renal phosphate excretion in chronic kidney disease leads to hyperphosphatemia, accelerating vascular calcification, renal osteodystrophy, and cardiovascular mortality.

Heart Disease — Observational and mechanistic evidence reviewed in PMC3278747 links high inorganic phosphate intake from food additives to endothelial dysfunction and vascular calcification, increasing cardiovascular risk.

Hypertension — The high sodium load of pentasodium triphosphate, combined with its contribution to total dietary phosphate, may exacerbate hypertension and associated end-organ damage.

Infants — EFSA specifically requested additional safety data for infants and young children (below 16 weeks of age) due to their immature renal phosphate-handling capacity and higher relative exposure per body weight.

Ibd — Polyphosphate additives may be hydrolysed to orthophosphate in the gut, potentially altering intestinal microbiota and mucosal barrier function, which is of particular concern in individuals with active inflammatory bowel disease.

Research citations

The sources behind this verdict.

1WHO. JECFA Food Additive Database: Pentasodium triphosphate (INS 451i). apps.who.int
2FAO. GSFA Online Food Additive Details: Pentasodium triphosphate (451(i)). fao.org
3EFSA. Re-evaluation of phosphoric acid–phosphates – di-, tri- and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use, 2019. efsa.europa.eu
4PubMed. Re-evaluation of phosphoric acid-phosphates – di-, tri- and polyphosphates (E 338–341, E 343, E 450–452) as food additives and the safety of proposed extension of use, 2019. pubmed.ncbi.nlm.nih.gov
5PubMed. Phosphate Additives in Food — a Health Risk, 2012. pmc.ncbi.nlm.nih.gov

Independently researched5 citations